Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Oncogenesis
SJR: 0.946 SNIP: 0.503 CiteScore™: 2

ISSN Печать: 0893-9675
ISSN Онлайн: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2014012423
pages 119-137

Histone Deacetylases and Cancer-Associated Angiogenesis: Current Understanding of the Biology and Clinical Perspectives

Andrei Turtoi
Metastasis Research Laboratory, GIGA Cancer, University of Liege, 4000 Liege, Belgium
Paul Peixoto
Metastasis Research Laboratory, GIGA Cancer, University of Liege, 4000 Liege, Belgium
Vincent Castronovo
Metastasis Research Laboratory, GIGA Cancer, University of Liege, 4000 Liege, Belgium
Akeila Bellahcene
Metastasis Research Laboratory, GIGA Cancer, University of Liege, 4000 Liege, Belgium

Краткое описание

Histone deacetylase enzymes (HDACs) have been shown to be important to the development and progression of human cancers. Angiogenesis is a vital process that facilitates tumor growth and survival. More than a dozen of different activators and inhibitors are involved in at least as many diverse mechanisms to control angiogenesis. HDACs directly or indirectly control many of these regulators. In the current review, we give a brief overview of molecular mechanisms of HDAC actions and link these to the current knowledge concerning HDAC-mediated regulation of tumor-associated angiogenesis. HDAC specific knockdown studies and the use of pan-HDAC inhibitors (HDACi) contributed to the identification of: (i) HDACs that are key to angiogenesis and (ii) their multiple protein targets essential for angiogenic process. The clinical development of HDACi is an active area of investigation. In the scope of this review, we highlight several preclinical studies that examine the anti-angiogenic role of HDACi. Certainly, there is still much to be learned about the use of HDACi to inhibit tumoral angiogenesis. Recent efforts in the clinics aiming to combine broad HDACi (mainly vorinostat, which is FDA approved for T-cell lymphoma) with other anti-angiogenic therapies could, however, bring the proof that the lack of specificity of pan-HDACi may not be a major issue as compared with (long-time idealized) selective inhibitors targeting one particular HDAC.

Ключевые слова: HDAC, preclinical, sirtuins, inhibitors

Articles with similar content:

Altered Expression of Histone Deacetylases in Cancer
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 1-2
Carmen Jeronimo, Rui Manuel Ferreira Henrique, Diana Montezuma
Modulation of Immune Responses by Histone Deacetylase Inhibitors
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 1-2
Heiko Brennenstuhl, Ulrike Naumann, Sonja Schotterl
The Role of the Leptin-Melanocortin Signalling Pathway in the Control of Food Intake
Critical Reviews™ in Eukaryotic Gene Expression, Vol.19, 2009, issue 4
Doreen Zegers, Sigri Beckers, Luc F. Van Gaal, Wim Van Hul
Dendritic Cell-Derived Exosomes as Cell-Free Peptide-Based Vaccines
Critical Reviews™ in Immunology, Vol.25, 2005, issue 3
Julien Taieb, Nathalie Chaput, Laurence Zitvogel
Traditional Concepts and Future Avenues of Glucocorticoid Action in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis Therapy
Critical Reviews™ in Immunology, Vol.29, 2009, issue 3
Fred Luhder, Holger Reichardt